Emergent BioSolutions, VaxGen deal

Emergent acquired VaxGen’s rPA102 anthrax vaccine and related assets for $2 million up front and up to $8 million in milestones, plus royalties. Emergent said the acquisition diversifies its anthrax portfolio. Emergent’s BioThrax anthrax vaccine adsorbed (AVA) is the only FDA-approved vaccine to prevent anthrax infection. Emergent also has two preclinical candidates to treat symptoms of anthrax: Anthrax Immune Globulin (AIG) and AVP 21D9, a human mAb against Bacillus anthracis protective antigen. ...